Search

Your search keyword '"Hoogendoorn, Mels"' showing total 7 results
Start Over Author "Hoogendoorn, Mels" Journal blood advances
7 results on '"Hoogendoorn, Mels"'

2. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J., Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W., Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J.F.M., Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W.J., Bargetzi, Mario, Klein, Saskia K., Gadisseur, Alain, Westerweel, Peter E., Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A., Hoogendoorn, Mels, Legdeur, Marie-Cecile J.C., Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T., Janssen, Jeroen J.W.M., Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J.M., van Elssen, Catharina H.M.J., Manz, Markus G., Floisand, Yngvar, and Ossenkoppele, Gert J.

Published
2021
Full Text
View/download PDF

3. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

Author

de Weerdt, Iris, Hofland, Tom, de Boer, Renate, Dobber, Johan A., Dubois, Julie, van Nieuwenhuize, Denise, Mobasher, Mehrdad, de Boer, Fransien, Hoogendoorn, Mels, Velders, Gerjo A., van der Klift, Marjolein, Remmerswaal, Ester B.M., Bemelman, Frederike J., Niemann, Carsten U., Kersting, Sabina, Levin, Mark-David, Eldering, Eric, Tonino, Sanne H., and Kater, Arnon P.

Published
2019
Full Text
View/download PDF

5. Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Author

Huls, Gerwin, primary, Chitu, Dana A., additional, Pabst, Thomas, additional, Klein, Saskia K., additional, Stussi, Georg, additional, Griskevicius, Laimonas, additional, Valk, Peter J. M., additional, Cloos, Jacqueline, additional, van de Loosdrecht, Arjan A., additional, Breems, Dimitri, additional, van Lammeren-Venema, Danielle, additional, van Zeventer, Isabelle, additional, Boersma, Rinske, additional, Jongen-Lavrencic, Mojca, additional, Fehr, Martin, additional, Hoogendoorn, Mels, additional, Manz, Markus G., additional, Söhne, Maaike, additional, van Marwijk Kooy, Rien, additional, Deeren, Dries, additional, van der Poel, Marjolein W. M., additional, Legdeur, Marie Cecile, additional, Tick, Lidwine, additional, Chalandon, Yves, additional, Ammatuna, Emanuele, additional, Blum, Sabine, additional, Löwenberg, Bob, additional, and Ossenkoppele, Gert J., additional

Published
2020
Full Text
View/download PDF

6. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

Author

Kater, Arnon P., primary, Kersting, Sabina, additional, van Norden, Yvette, additional, Dubois, Julie, additional, Dobber, Johan A., additional, Mellink, Clemens H., additional, Evers, Ludo M., additional, Croon-de Boer, Fransien, additional, Schreurs, John, additional, van der Spek, Ellen, additional, Visser, Hein, additional, Idink, Cecile, additional, Wittebol, Shulamiet, additional, Hoogendoorn, Mels, additional, Tonino, Sanne H., additional, Mobasher, Mehrdad, additional, and Levin, Mark-David, additional

Published
2018
Full Text
View/download PDF

7. Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells

Author

van Bruggen, J.A.C., van der Windt, G.J.W., Hoogendoorn, Mels, Dubois, J., Kater, Arnon P., and Peters, F.S.

Abstract

Acquired T-cell dysfunction is characteristic of CLL and is associated with reduced efficacy of T-cell based therapies. A recently described feature of dysfunctional CLL-derived CD8 T cells is reduced metabolic plasticity. To what extend CD4 T cells are affected, and if CD4 T-cell metabolism and function can be restored upon clinical depletion of CLL cells is currently unknown. Here we address these unresolved issues by a comprehensive phenotypic, metabolic, transcriptomic and functional analysis of CD4 T cells of untreated CLL patients, and by analyzing the effects of venetoclax + obinutuzumab on the CD4 population. Resting CD4 T cells derived from CLL patients expressed lower levels of GLUT-1, displayed deteriorated oxidative phosphorylation (OXPHOS) and overall reduced mitochondrial fitness. Upon T-cell stimulation, CLL T cells were unable to initiate glycolysis. Transcriptome analysis revealed that depletion of CLL cells in vitroresulted in upregulation of OXPHOS and glycolysis pathways and restored T-cell function in vitro. Analysis of CD4 T cells from CLL patients prior and after venetoclax + obinutuzumab treatment, which led to effective clearance of CLL in blood and bone marrow, revealed recovery of T-cell activation and restoration of the switch to glycolysis, as well as improved T-cell proliferation. Collectively these data demonstrate that CLL cells impose metabolic restrictions on CD4 T cells which lead to reduced CD4 T-cell functionality. This trial is registered in the Netherlands Trial Registry ID: NTR6043.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results